Markus, Richard
Chow, Vincent
Pan, Zhiying
Hanes, Vladimir
Funding for this research was provided by:
Amgen Inc.
Article History
Received: 21 June 2017
Accepted: 3 August 2017
First Online: 1 September 2017
Change Date: 20 November 2017
Change Type: Correction
Change Date: 20 November 2017
Change Type: Erratum
Change Details: The article [A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men]
Change Details: The article [A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult men]
Compliance with ethical standards
:
: Richard Markus, Vincent Chow, Zhiying Pan, and Vladimir Hanes are employees and stockholders of Amgen Inc.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: This study was funded by Amgen Inc., Thousand Oaks, CA.